{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-26-000059","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.196258+00:00","generated_at":"2026-05-15T00:36:28.270957+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Q1 revenue $156.1M (-30% YoY); net income slumps 90%; guidance raised on adjusted EBITDA","bullets":["Revenue $156.1M vs $222.2M in Q1 2025; net income $6.8M ($0.07 EPS) vs $68.0M ($1.19 EPS).","Smallpox MCM revenue down 40% to $64.2M; Anthrax MCM down 55% to $21.6M.","Adjusted EBITDA $35.6M (23% margin) vs $79.1M (36% margin) in Q1 2025.","FY 2026 adjusted net income guidance raised to $45-65M (from $25-45M); FY 2026 adjusted EBITDA guidance raised to $155-175M (from $135-155M).","Completed debt refinancing with $150M term loan; secured over $200M in new U.S./Canada government contracts."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-26-000059","json":"https://secwatch.observer/filing/0001367644-26-000059.json","markdown":"https://secwatch.observer/filing/0001367644-26-000059.md","text":"https://secwatch.observer/filing/0001367644-26-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/0001367644-26-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/ebs-20260430.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:36:28.270957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0aa1d4109a4932d26594e55b92cd3cb34a467e8a","claim":"Emergent BioSolutions Inc. reported first quarter ended March 31, 2026 results: revenue $156.1 million, net income $6.8 million, EPS $0.07.","evidence_excerpt":"and is incorporated herein by reference. --- EX-99.1 (EX-99.1) --- EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS • First Quarter 2026 Total Revenues of $156.1 million • First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% • First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23% GAITHERSBURG,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/0001367644-26-000059-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$156.1 million"},{"label":"Net income","value":"$6.8 million"},{"label":"EPS","value":"$0.07"},{"label":"Result","value":"reported results"}]},{"claim_id":"6045e852e20bb42017a63f761e0196b65e68f758","claim":"Emergent BioSolutions Inc. reported Q1 2026 results: revenue $156.1, net income $6.8, EPS 0.07.","evidence_excerpt":"($ in millions, except per share amounts) Q1 2026 Q1 2025 % Change Total Revenues $ 156.1 $ 222.2 (30) % Net Income $ 6.8 $ 68.0 (90) % Net Income per Diluted Share $ 0.07 $ 1.19 (94) %","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/0001367644-26-000059-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q1 2026"},{"label":"Revenue","value":"$156.1"},{"label":"Net income","value":"$6.8"},{"label":"EPS","value":"0.07"},{"label":"Result","value":"reported results"}]},{"claim_id":"a2e9f0501fc8f98ff921ac330c7d3aa120202752","claim":"Emergent BioSolutions Inc. reported First Quarter 2026 results: revenue $156.1 million, net income $6.8 million, EPS $0.07.","evidence_excerpt":"First Quarter 2026 Total Revenues of $156.1 million • First Quarter 2026 Net Income of $6.8 million and Net Income Margin of 4% • First Quarter 2026 Adjusted EBITDA of $35.6 million and Adjusted EBITDA Margin of 23%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764426000059/0001367644-26-000059-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First Quarter 2026"},{"label":"Revenue","value":"$156.1 million"},{"label":"Net income","value":"$6.8 million"},{"label":"EPS","value":"$0.07"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}